Review



unbound human vegf  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    R&D Systems unbound human vegf
    Schematic representation and biochemical characterization of traps. A Basic protein structure of traps. <t>VEGF-trap</t> is composed of the VEGF-binding region (domain 2 and 3 of VEGFR-1 and -2, respectively) and the Fc region of IgG1 (CH2 and CH3 domains). The Sticky-traps, Sticky-trap68, Sticky-trap78 and Sticky-trap678 contain the heparin-binding domains (HBDs) encoded by exons 6 and 8, 7 and 8, and 6, 7 and 8 of vascular endothelial growth factor, respectively. See Supplementary Fig S1A and methods for further details. <t>B–D</t> <t>Affinity</t> of traps to extracellular matrix (ECM). (B) Immunostaining (red signal) and Western blot analysis (on the right of the image) of traps in PC-3 cell monolayers and conditioned supernatant, respectively. Similar results are shown in Supplementary Fig S4A for the A-673 transgenic lines. Plus (+) dox samples were collected 48 h after addition of doxycycline-containing media. Scale bar, 100 μm. (C) Binding of recombinant traps to ECM. (D) Affinity of recombinant traps to heparin-Sepharose column. E, F Assessment of traps ability to bind human VEGF. (E) Free VEGF levels in the conditioned of PC-3 cancer transgenic cell lines, co-cultured of wild-type PC-3 cells. Media were collected after 48 h of culture with or without the addition of doxycycline. (F) Binding affinity (KD) of recombinant traps to human VEGF 165 (VEGF-trap; 9.0 pM, Short-trap; 12.2 pM, and Sticky-trap 13.9 pM). G Inhibition of VEGF-induced human umbilical vein endothelial cells proliferation by recombinant traps. Source data are available online for this figure.
    Unbound Human Vegf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1226 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/unbound human vegf/product/R&D Systems
    Average 97 stars, based on 1226 article reviews
    unbound human vegf - by Bioz Stars, 2026-02
    97/100 stars

    Images

    1) Product Images from "Local acting Sticky-trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye"

    Article Title: Local acting Sticky-trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye

    Journal: EMBO Molecular Medicine

    doi: 10.1002/emmm.201303708

    Schematic representation and biochemical characterization of traps. A Basic protein structure of traps. VEGF-trap is composed of the VEGF-binding region (domain 2 and 3 of VEGFR-1 and -2, respectively) and the Fc region of IgG1 (CH2 and CH3 domains). The Sticky-traps, Sticky-trap68, Sticky-trap78 and Sticky-trap678 contain the heparin-binding domains (HBDs) encoded by exons 6 and 8, 7 and 8, and 6, 7 and 8 of vascular endothelial growth factor, respectively. See Supplementary Fig S1A and methods for further details. B–D Affinity of traps to extracellular matrix (ECM). (B) Immunostaining (red signal) and Western blot analysis (on the right of the image) of traps in PC-3 cell monolayers and conditioned supernatant, respectively. Similar results are shown in Supplementary Fig S4A for the A-673 transgenic lines. Plus (+) dox samples were collected 48 h after addition of doxycycline-containing media. Scale bar, 100 μm. (C) Binding of recombinant traps to ECM. (D) Affinity of recombinant traps to heparin-Sepharose column. E, F Assessment of traps ability to bind human VEGF. (E) Free VEGF levels in the conditioned of PC-3 cancer transgenic cell lines, co-cultured of wild-type PC-3 cells. Media were collected after 48 h of culture with or without the addition of doxycycline. (F) Binding affinity (KD) of recombinant traps to human VEGF 165 (VEGF-trap; 9.0 pM, Short-trap; 12.2 pM, and Sticky-trap 13.9 pM). G Inhibition of VEGF-induced human umbilical vein endothelial cells proliferation by recombinant traps. Source data are available online for this figure.
    Figure Legend Snippet: Schematic representation and biochemical characterization of traps. A Basic protein structure of traps. VEGF-trap is composed of the VEGF-binding region (domain 2 and 3 of VEGFR-1 and -2, respectively) and the Fc region of IgG1 (CH2 and CH3 domains). The Sticky-traps, Sticky-trap68, Sticky-trap78 and Sticky-trap678 contain the heparin-binding domains (HBDs) encoded by exons 6 and 8, 7 and 8, and 6, 7 and 8 of vascular endothelial growth factor, respectively. See Supplementary Fig S1A and methods for further details. B–D Affinity of traps to extracellular matrix (ECM). (B) Immunostaining (red signal) and Western blot analysis (on the right of the image) of traps in PC-3 cell monolayers and conditioned supernatant, respectively. Similar results are shown in Supplementary Fig S4A for the A-673 transgenic lines. Plus (+) dox samples were collected 48 h after addition of doxycycline-containing media. Scale bar, 100 μm. (C) Binding of recombinant traps to ECM. (D) Affinity of recombinant traps to heparin-Sepharose column. E, F Assessment of traps ability to bind human VEGF. (E) Free VEGF levels in the conditioned of PC-3 cancer transgenic cell lines, co-cultured of wild-type PC-3 cells. Media were collected after 48 h of culture with or without the addition of doxycycline. (F) Binding affinity (KD) of recombinant traps to human VEGF 165 (VEGF-trap; 9.0 pM, Short-trap; 12.2 pM, and Sticky-trap 13.9 pM). G Inhibition of VEGF-induced human umbilical vein endothelial cells proliferation by recombinant traps. Source data are available online for this figure.

    Techniques Used: Binding Assay, Immunostaining, Western Blot, Transgenic Assay, Recombinant, Cell Culture, Inhibition

    Pharmacokinetic profile and tissue distribution of traps. A Traps (100 μg) were injected subcutaneously into C57BL/6J mice, and serum levels were estimated using an ELISA assay. Error bars represent s.e.m. ( n = 5). B Serum levels of VEGF at various time points after subcutaneous injection of traps (100 μg) into C57BL/6J mice. Error bars represent s.e.m. ( n = 5; *** P < 0.001, one-way ANOVA). C–F Trap levels in various tissues 48 h post-subcutaneous injection of traps (100 μg) into C57BL/6J mice. Error bars represent s.e.m. ( n = 5; *** P < 0.001, one-way ANOVA).
    Figure Legend Snippet: Pharmacokinetic profile and tissue distribution of traps. A Traps (100 μg) were injected subcutaneously into C57BL/6J mice, and serum levels were estimated using an ELISA assay. Error bars represent s.e.m. ( n = 5). B Serum levels of VEGF at various time points after subcutaneous injection of traps (100 μg) into C57BL/6J mice. Error bars represent s.e.m. ( n = 5; *** P < 0.001, one-way ANOVA). C–F Trap levels in various tissues 48 h post-subcutaneous injection of traps (100 μg) into C57BL/6J mice. Error bars represent s.e.m. ( n = 5; *** P < 0.001, one-way ANOVA).

    Techniques Used: Injection, Enzyme-linked Immunosorbent Assay



    Similar Products

    unbound human vegf  (R&D Systems)
    97
    R&D Systems unbound human vegf
    Schematic representation and biochemical characterization of traps. A Basic protein structure of traps. <t>VEGF-trap</t> is composed of the VEGF-binding region (domain 2 and 3 of VEGFR-1 and -2, respectively) and the Fc region of IgG1 (CH2 and CH3 domains). The Sticky-traps, Sticky-trap68, Sticky-trap78 and Sticky-trap678 contain the heparin-binding domains (HBDs) encoded by exons 6 and 8, 7 and 8, and 6, 7 and 8 of vascular endothelial growth factor, respectively. See Supplementary Fig S1A and methods for further details. <t>B–D</t> <t>Affinity</t> of traps to extracellular matrix (ECM). (B) Immunostaining (red signal) and Western blot analysis (on the right of the image) of traps in PC-3 cell monolayers and conditioned supernatant, respectively. Similar results are shown in Supplementary Fig S4A for the A-673 transgenic lines. Plus (+) dox samples were collected 48 h after addition of doxycycline-containing media. Scale bar, 100 μm. (C) Binding of recombinant traps to ECM. (D) Affinity of recombinant traps to heparin-Sepharose column. E, F Assessment of traps ability to bind human VEGF. (E) Free VEGF levels in the conditioned of PC-3 cancer transgenic cell lines, co-cultured of wild-type PC-3 cells. Media were collected after 48 h of culture with or without the addition of doxycycline. (F) Binding affinity (KD) of recombinant traps to human VEGF 165 (VEGF-trap; 9.0 pM, Short-trap; 12.2 pM, and Sticky-trap 13.9 pM). G Inhibition of VEGF-induced human umbilical vein endothelial cells proliferation by recombinant traps. Source data are available online for this figure.
    Unbound Human Vegf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/unbound human vegf/product/R&D Systems
    Average 97 stars, based on 1 article reviews
    unbound human vegf - by Bioz Stars, 2026-02
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    Schematic representation and biochemical characterization of traps. A Basic protein structure of traps. VEGF-trap is composed of the VEGF-binding region (domain 2 and 3 of VEGFR-1 and -2, respectively) and the Fc region of IgG1 (CH2 and CH3 domains). The Sticky-traps, Sticky-trap68, Sticky-trap78 and Sticky-trap678 contain the heparin-binding domains (HBDs) encoded by exons 6 and 8, 7 and 8, and 6, 7 and 8 of vascular endothelial growth factor, respectively. See Supplementary Fig S1A and methods for further details. B–D Affinity of traps to extracellular matrix (ECM). (B) Immunostaining (red signal) and Western blot analysis (on the right of the image) of traps in PC-3 cell monolayers and conditioned supernatant, respectively. Similar results are shown in Supplementary Fig S4A for the A-673 transgenic lines. Plus (+) dox samples were collected 48 h after addition of doxycycline-containing media. Scale bar, 100 μm. (C) Binding of recombinant traps to ECM. (D) Affinity of recombinant traps to heparin-Sepharose column. E, F Assessment of traps ability to bind human VEGF. (E) Free VEGF levels in the conditioned of PC-3 cancer transgenic cell lines, co-cultured of wild-type PC-3 cells. Media were collected after 48 h of culture with or without the addition of doxycycline. (F) Binding affinity (KD) of recombinant traps to human VEGF 165 (VEGF-trap; 9.0 pM, Short-trap; 12.2 pM, and Sticky-trap 13.9 pM). G Inhibition of VEGF-induced human umbilical vein endothelial cells proliferation by recombinant traps. Source data are available online for this figure.

    Journal: EMBO Molecular Medicine

    Article Title: Local acting Sticky-trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye

    doi: 10.1002/emmm.201303708

    Figure Lengend Snippet: Schematic representation and biochemical characterization of traps. A Basic protein structure of traps. VEGF-trap is composed of the VEGF-binding region (domain 2 and 3 of VEGFR-1 and -2, respectively) and the Fc region of IgG1 (CH2 and CH3 domains). The Sticky-traps, Sticky-trap68, Sticky-trap78 and Sticky-trap678 contain the heparin-binding domains (HBDs) encoded by exons 6 and 8, 7 and 8, and 6, 7 and 8 of vascular endothelial growth factor, respectively. See Supplementary Fig S1A and methods for further details. B–D Affinity of traps to extracellular matrix (ECM). (B) Immunostaining (red signal) and Western blot analysis (on the right of the image) of traps in PC-3 cell monolayers and conditioned supernatant, respectively. Similar results are shown in Supplementary Fig S4A for the A-673 transgenic lines. Plus (+) dox samples were collected 48 h after addition of doxycycline-containing media. Scale bar, 100 μm. (C) Binding of recombinant traps to ECM. (D) Affinity of recombinant traps to heparin-Sepharose column. E, F Assessment of traps ability to bind human VEGF. (E) Free VEGF levels in the conditioned of PC-3 cancer transgenic cell lines, co-cultured of wild-type PC-3 cells. Media were collected after 48 h of culture with or without the addition of doxycycline. (F) Binding affinity (KD) of recombinant traps to human VEGF 165 (VEGF-trap; 9.0 pM, Short-trap; 12.2 pM, and Sticky-trap 13.9 pM). G Inhibition of VEGF-induced human umbilical vein endothelial cells proliferation by recombinant traps. Source data are available online for this figure.

    Article Snippet: Binding affinity of traps was determined using an ELISA able to detect unbound human VEGF (R&D Systems, cat. # DVE00).

    Techniques: Binding Assay, Immunostaining, Western Blot, Transgenic Assay, Recombinant, Cell Culture, Inhibition

    Pharmacokinetic profile and tissue distribution of traps. A Traps (100 μg) were injected subcutaneously into C57BL/6J mice, and serum levels were estimated using an ELISA assay. Error bars represent s.e.m. ( n = 5). B Serum levels of VEGF at various time points after subcutaneous injection of traps (100 μg) into C57BL/6J mice. Error bars represent s.e.m. ( n = 5; *** P < 0.001, one-way ANOVA). C–F Trap levels in various tissues 48 h post-subcutaneous injection of traps (100 μg) into C57BL/6J mice. Error bars represent s.e.m. ( n = 5; *** P < 0.001, one-way ANOVA).

    Journal: EMBO Molecular Medicine

    Article Title: Local acting Sticky-trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye

    doi: 10.1002/emmm.201303708

    Figure Lengend Snippet: Pharmacokinetic profile and tissue distribution of traps. A Traps (100 μg) were injected subcutaneously into C57BL/6J mice, and serum levels were estimated using an ELISA assay. Error bars represent s.e.m. ( n = 5). B Serum levels of VEGF at various time points after subcutaneous injection of traps (100 μg) into C57BL/6J mice. Error bars represent s.e.m. ( n = 5; *** P < 0.001, one-way ANOVA). C–F Trap levels in various tissues 48 h post-subcutaneous injection of traps (100 μg) into C57BL/6J mice. Error bars represent s.e.m. ( n = 5; *** P < 0.001, one-way ANOVA).

    Article Snippet: Binding affinity of traps was determined using an ELISA able to detect unbound human VEGF (R&D Systems, cat. # DVE00).

    Techniques: Injection, Enzyme-linked Immunosorbent Assay